IN VITRO SCREENING OF CHEMO AGENTS FOR ACTIVITY

Information

  • Research Project
  • 6096051
  • ApplicationId
    6096051
  • Core Project Number
    N01CN095104
  • Full Project Number
    N01CN095104-000
  • Serial Number
    95104
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/30/1999 - 25 years ago
  • Project End Date
    -
  • Program Officer Name
  • Budget Start Date
    6/30/1999 - 25 years ago
  • Budget End Date
    12/30/2000 - 23 years ago
  • Fiscal Year
    1999
  • Support Year
  • Suffix
  • Award Notice Date
    -

IN VITRO SCREENING OF CHEMO AGENTS FOR ACTIVITY

Angiogenesis is the growth of new blood vessels from existing ones. It is an important aspect of new tissue development, tissue growth, and tissue repair. It is also a component of many diseases, including cancer. Angiogenesis is necessary for the growth of tumors and their metastasis. The induction of Angiogenesis is mediated by angiogenic growth factors produced by either tumor or host cells.Chemopreventive, agents which inhibit or retard Angiogenesis are urgently needed. The purpose of this project is to screen selected chemopreventive agents for antiangiogenic activity in vitro. A main concern in the development of antiangiogenic therapies is the availability of sensitive and specific disease models. The present project focuses on the utilization of in vitro assay systems that can be used to screen antiangiogenic drugs. These in vitro assay systems include but are not limited to 1) chorioallantoic membrane in shelled or shelled - less chick embryos, 2) explants of rat aorta embedded in collagen gel grown in serum - free media, and 3) The contractor is using the most sensitive system of their choice, wherein the effects of the antiangiogenic factors are quantitated. For each agent, the system of choice shall be first calibrated in the presence of a well defined angiogenic factor as a positive control and in the absence of such factor as a negative control. The system of choice includes the presence of human tumor cells as a positive control. The absence of human tumor cells constitutes a negative control. The human tumor being used represent highly malignant cells or it consists of dysplastic cells. Human tumor cells that arose from early to moderate dysplastic lesions are preferred, provided that such cells have been shown to elicit angiogenesis in vitro.

IC Name
DIVISION OF CANCER PREVENTION AND CONTROL
  • Activity
    N01
  • Administering IC
    CN
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    399
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
  • Study Section Name
  • Organization Name
    ALION SCIENCE AND TECHNOLOGY CORP
  • Organization Department
  • Organization DUNS
    119162332
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27713
  • Organization District
    UNITED STATES